Sort
48,018 grants matching “immunotherapy”
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma
$370,500Roger S Lo · University Of California Los Angeles · R01 · FY2021 · CA
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
$370,500Andrew E Aplin · Thomas Jefferson University · R01 · FY2020 · CA
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma
$370,500Roger S Lo · University Of California Los Angeles · R01 · FY2019 · CA
Exploiting public genomic and transcriptomic data to uncover cancer-RNA editing relationships
$370,500Xinshu Grace Xiao · University Of California Los Angeles · R01 · FY2024 · CA
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
$370,500Andrew E Aplin · Thomas Jefferson University · R01 · FY2018 · CA
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma
$370,500Roger S Lo · University Of California Los Angeles · R01 · FY2020 · CA
Develop a Therapeutic Nano-vaccine against Head and Neck Cancer
$370,500Yu Leo Lei · University Of Michigan At Ann Arbor · R01 · FY2020 · DE
The B7x pathways in the tumor microenvironment
$370,440Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2023 · CA
Enhancing mitochondrial metabolism to improve anti-tumor CD8 immune response
$370,439Mercedes R. Rincon · University Of Colorado Denver · R01 · FY2023 · CA
T Cell Targeting for GVHD
$370,402Bruce R. Blazar · University Of Minnesota · R01 · FY2011 · HL
Immunopharmacotherapy for the Treatment of Cocaine Abuse
$370,400Scripps Research Institute · R01 · FY2003 · DA
Immunopharmacotherapy for the Treatment of Cocaine Abuse
$370,400Scripps Research Institute · R01 · FY2002 · DA
Stimulating Lymphocyte Activation Combined with Inhibition of Immunosuppressive Signals in Colon Cancer Metastases
$370,370Ajay V. Maker · University Of California, San Francisco · R37 · FY2023 · CA
Tumor evolution in response to treatment
$370,354Lichun Ma · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Immunology of aging and immunotherapy of aging-associated diseases
$370,353Arya Biragyn · National Institute On Aging · ZIA · FY2018 · AG
Targeting metabolic stress to induce pancreatic tumor cell death
$370,329Costas Andreas Lyssiotis · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Targeting the colchicine binding site in tubulin for cancer therapy
$370,326Wei Li · University Of Tennessee Health Sci Ctr · R01 · FY2024 · CA
Integrating Low-Cost Paper-Based Devices and Personalized Immunotherapeutics to Treat Triple Negative Breast Cancer
$370,300Brian Richard McNaughton · Delaware State University · U54 · FY2023 · MD
Characterization of the interaction between inflammation and cancer progression
$370,298Robert Wiltrout · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Mechanistic difference of NF-kappaB in lung physiology and tumorigenesis
$370,274Zhaoxia Qu · University Of Southern California · R01 · FY2024 · CA
Mechanisms of Arginine Deprivation in Small Cell Lung Cancer
$370,215Trudy Gale Oliver · Duke University · R01 · FY2024 · CA
X-ray/optical tomographic guidance and assessment for pre-clinical radiation research
$370,209Ken Kang-Hsin Wang · Johns Hopkins University · R37 · FY2019 · CA
A NOVEL TUMOR ANTIGEN AND FOXP3 DUAL TARGETING TUMOR CELL VACCINE ENHANCES THE IMMUNOTHERAPY IN A MURINE MODEL OF RENAL CELL CARCINOMA
$370,143Health Research, Inc. · · FY2013 · Department of Defense
T Cell Immunity in Endemic Burkitt Lymphoma
$370,134Ann M Moormann · Case Western Reserve University · R01 · FY2009 · CA
Mechanisms Underlying the Role of Interleukin-7 in Type 1 Diabetes
$370,125Hans Peter Dooms · Boston University Medical Campus · R01 · FY2017 · DK